Detail akcie Verona Sp ADR online

Business Summary: Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Verona Pharma PLC - ADR revenues increased from $0K to $76.3M. Net loss decreased 37% to $16.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Drug Development segment loss decrease of 62% to $10.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.04 to -$0.02.